Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.

Trial Details

NCT ID
NCT07081984
Phase
PHASE1
Sponsor
Therorna
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • therapeutic tumor vaccine
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients must meet all the following inclusion criteria to be eligible for participation in this study:
  • The patient provides written informed consent for the study.
  • Willing to comply with the visit plans, treatment plans, and other requirements of the study schedule.
  • Previous HPV16+ solid tumors.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →